Share to
  • Email
  • Facebook
  • X
  • Bluesky
  • Instagram
  • LinkedIn
Share to
  • Email
  • Facebook
  • X
  • Bluesky
  • Instagram
  • LinkedIn
Back to Test Catalogue
Test ID: METHO

Methotrexate, Serum/Plasma

Test Overview

Clinical Utility

Refer to BC Cancer Methotrexate Monograph and Cancer Care Ontario at external websites.

Method

Competitive binding enzyme immunoassay

Result Included

Methotrexate

Specimen

Specimen Type

Gel-separator tubes are not acceptable
Serum
Plasma

Containers

Preferred Containers

Red Top (no additive)

Acceptable Containers

Green top (Na Heparin); Green top (Li Heparin); Lavender top (EDTA)

Volume

Sample Volume

1 mL

Minimum Volume

0.5 mL

Specimen Comment

<b>Avoid gel separator tubes.</b>

Collection & Handling

Collection Instructions

Collect at 24, 48 and 72 hrs following high I.V. dose.

Handling Information

Separate within 2 hours of collection. Specimen must be labelled inside and outside of the light protecting wrap. Store and submit specimen protected from light in an amber vial.

Additional Information

The sampling of Methotrexate is dependent on dose, duration of infusion and clinical status of the patient.

Stability

Ambient Refrigerated Frozen
2 days 14 days 1 month

Rejection Criteria

Criteria Specification
Specimen Not protected from light or collected with gel-separator

Performance & Interpretation

Turnaround Time

2 days

Results

Name
Units
Reference Range
Conversion
  1. Methotrexate
    µmol/L
    Potential toxicity following high-dose methotrexate dosing:

    24 hours: ≥ 10

    48 hours: ≥ 1

    72 hours: > 0.1

    Comment

    Refer to BC Cancer Methotrexate Monograph and Cancer Care Ontario at external websites.

Referral Location

Canada

Interface & Setup

HL7 Interface Codes

Order Code Result Name Result Codes Units
METHO Methotrexate 3163 umol/L

Test Version

Last Updated

2023-09-18